Patisiran can preserve functional capacity in transthyretin amyloidosis, according to study
For patients with transthyretin amyloidosis (ATTR amyloidosis), administration of an RNA interference therapeutic agent, patisiran, over 12 months results in preserved functional capacity, according to a study published in ...
Oct 27, 2023
0
0